AI Article Synopsis
- - Mycobacterium tuberculosis (Mtb) can remain dormant in the body and reactivate later, creating the need for new prevention strategies.
- - In a study, B6D2F1 mice were infected with a low dose of Mtb and later treated with recombinant adenoviruses that delivered TNFα, β defensin-3, and LL37.
- - The mice that received the adenovirus treatment had significantly lower bacterial loads and less pneumonia compared to controls, particularly with TNFα and LL37 being the most effective, suggesting that gene therapy targeting inflammation or antimicrobial peptides could help prevent latent tuberculosis reactivation.
Article Abstract
Mycobacterium tuberculosis (Mtb) latent infection can lead to reactivation. The design of new strategies to prevent it is an important subject. B6D2F1 mice were infected intratracheally with a low dose of Mtb H37Rv to induce chronic infection. After 7 months, mice were treated with one dose of recombinant adenoviruses encoding TNFα, β defensin-3 and LL37. Immunosupression was induced 1 month later with corticosterone. In comparison with the control group, mice treated with adenoviruses showed significantly less bacterial load and pneumonia, the adenoviruses encoding TNFα and LL37 being the most efficient. Gene therapy based in a proinflammatory cytokine or antimicrobial peptides is a potentially useful system to prevent reactivation of latent tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/femspd/ftw075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!